A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma | Zendy

Simon J. Crabb | Zendy; Syed A. Hussain | Zendy; Eileen Soulis | Zendy; Samantha Hinsley | Zendy; Laura Dempsey | Zendy; Avril Trevethan | Zendy; YeePei Song | Zendy; Jim Barber | Zendy; J. Frew | Zendy; Joanna Gale | Zendy; Guy Faust | Zendy; Susannah Brock | Zendy; Ursula McGovern | Zendy; Omi Parikh | Zendy; Deborah Enting | Zendy; Santhanam Sundar | Zendy; Gihan Ratnayake | Zendy; Kathryn Lees | Zendy; Alison Birtle | Zendy; Thomas Powles | Zendy; Robert J. Jones | Zendy

Open Access

A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma

Author(s) -

Simon J. Crabb,

Syed A. Hussain,

Eileen Soulis,

Samantha Hinsley,

Laura Dempsey,

Avril Trevethan,

YeePei Song,

Jim Barber,

J. Frew,

Joanna Gale,

Guy Faust,

Susannah Brock,

Ursula McGovern,

Omi Parikh,

Deborah Enting,

Santhanam Sundar,

Gihan Ratnayake,

Kathryn Lees,

Alison Birtle,

Thomas Powles,

Robert J. Jones

Publication year - 2022

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.22.00405

Subject(s) - medicine , hazard ratio , parp inhibitor , biomarker , placebo , chemotherapy , population , oncology , clinical endpoint , progression free survival , cancer , adverse effect , metastatic urothelial carcinoma , gastroenterology , surgery , randomized controlled trial , poly adp ribose polymerase , pathology , bladder cancer , confidence interval , biology , biochemistry , alternative medicine , environmental health , polymerase , gene , urothelial carcinoma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research